Managing The Skin Toxicities From New Melanoma Drugs
Managing The Skin Toxicities From New Melanoma Drugs
About this item
Full title
Author / Creator
Publisher
Boston: Springer US
Journal title
Language
English
Formats
Publication information
Publisher
Boston: Springer US
Subjects
More information
Scope and Contents
Contents
Opinion Statement
Patients treated with ipilimumab or targeted inhibitors of the RAF-MEK-ERK pathway (vemurafenib, dabrafenib, and trametinib) for advanced cutaneous melanoma often experience drug-related skin toxicities denoted as dermatologic adverse events (DAEs). Although rarely life-threatening, DAEs may emerge dramatically and potentially...
Alternative Titles
Full title
Managing The Skin Toxicities From New Melanoma Drugs
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1532419693
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1532419693
Other Identifiers
ISSN
1527-2729
E-ISSN
1534-6277,1534-5277
DOI
10.1007/s11864-014-0284-6
